Author

L. Pessaint

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 19 Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 22 Research Focus:host-pathogen & immune response· 22 Organism:non-human primate· 12 Assay:proteomics· 10 Research Focus:drug response / drug discovery· 7 Organism:rat· 7 Research Focus:benchmarking· 2 Organism:mouse· 2

Frequent Co-Authors

H. Andersen· 18 shared A. Cook· 16 shared M. G. Lewis· 12 shared A. Dodson· 9 shared A. Van Ry· 9 shared M. Gagne· 8 shared K. E. Foulds· 7 shared S. F. Andrew· 7 shared

Activity by Year

2020-2023 · peak 13/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

18 shared papersImmunology

H. Andersen

Mutual co-authors in cluster

Author profile →

22 papers

Recent·Most cited

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

J. I. Moliva, S. F. Andrew, B. J. Flynn, D. A. Wagner, K. E. Foulds, M. Gagne, D. R. Flebbe, E. Lamb, S. Provost, J. Marquez, A. Mychalowych, C. Lorag, C. C. Honeycutt, M. R. Burnett, L. McCormick, , Nason

This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.

bioRxiv · Nov 22, 2023 · PreprintImmunology

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates

M. Gagne, B. J. Flynn, S. F. Andrew, D. R. Flebbe, A. Mychalowych, E. Lamb, M. E. Davis-Gardner, M. R. Burnett, L. A. Serebryannyy, B. C. Lin, L. Pessaint, J.-P. M. Todd, Z. E. Ziff, E. Maule, R. Carroll, , M Suthar

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

bioRxiv · Nov 6, 2023 · PreprintImmunology

RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

M. Gagne, B. J. Flynn, C. C. Honeycutt, D. R. Flebbe, S. F. Andrew, S. J. Provost, L. McCormick, A. Van Ry, E. McCarthy, J.-P. M. Todd, S. Bao, I.-T. Teng, S. Marciano, Y. Rudich, C. Li, , D. C. Douek

RBD-62, a high-affinity ACE2 antagonist, limits SARS-CoV-2 replication in both upper and lower airways in rhesus macaques without blocking memory responses or causing anti-drug immunity.

bioRxiv · Jun 9, 2023 · PreprintImmunology

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

J. Misasi, R. R. Wei, L. Wang, A. Pegu, C.-J. Wei, O. Oloniniyi, T. Zhou, J. I. Moliva, B. Zhao, M. Choe, E. S. Yang, Y. Zhang, M. Boruszczak, M. Chen, K. Leung, , N. J. Sullivan

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

bioRxiv · Jul 29, 2022 · PreprintImmunology

Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques

A. Chandrashekar, J. Yu, K. McMahan, C. Jacob-Dolan, J. Liu, X. He, D. Hope, T. Anioke, J. Barrett, B. Chung, N. Hachmann, M. Lifton, J. Miller, O. Powers, M. Sciacca, , D. H. Barouch

This study evaluates vaccine efficacy against SARS-CoV-2 Omicron in macaques, finding that both humoral and cellular immune responses are necessary for virologic control.

bioRxiv · Feb 6, 2022Microbiology

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron

M. Gagne, J. I. Moliva, K. E. Foulds, S. F. Andrew, B. J. Flynn, A. P. Werner, D. A. Wagner, I.-T. Teng, B. C. Lin, C. Moore, N. Jean-Baptiste, R. Carroll, S. L. Foster, M. Patel, M. Ellis, , Naisan

This study compares B cell responses and protection against Omicron after boosting vaccinated macaques with mRNA-1273 or mRNA-Omicron vaccines, finding comparable immunity and protection.

bioRxiv · Feb 3, 2022 · PreprintImmunology

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

M. Gagne, K. S. Corbett, B. J. Flynn, K. E. Foulds, D. A. Wagner, S. F. Andrew, J.-P. M. Todd, C. C. Honeycutt, L. McCormick, S. T. Nurmukhambetova, M. E. Davis-Gardner, L. Pessaint, K. W. Bock, B. M. Nagata, M. Minai, , B. S. Graham

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

bioRxiv · Oct 23, 2021 · PreprintImmunology

An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant viral replication in rhesus macaques

Y. Sui, J. Li, H. Andersen, R. Zhang, S. Prabhu, T. Hoang, D. Venzon, A. Cook, R. Brown, E. Teow, J. Velasco, L. Pessaint, I. Moore, L. lagenaur, J. Talton, , J. Berzofsky

An intranasal SARS-CoV-2 beta variant subunit booster vaccine induced protective immunity against beta variant infection in rhesus macaques one year after initial vaccination.

bioRxiv · Oct 19, 2021Immunology

Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1

A. To, T. A. S. Wong, M. M. Lieberman, K. S. Thompson, L. Pessaint, J. Greenhouse, N. Daham, A. Cook, B. Narvaez, Z. Flinchbaugh, A. Van Ry, J. Yalley-Ogunro, H. Andersen, C.-Y. Lai, O. Donini, A. T. Lehrer

A recombinant subunit vaccine with CoVaccine HT adjuvant provides durable, broad neutralizing antibodies against SARS-CoV-2 VOCs in macaques, outperforming natural infection in protection and viral load reduction.

bioRxiv · Sep 24, 2021Immunology

Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Proteinco-immunization in rhesus macaques

M. Rosati, M. Agarwal, X. Hu, S. Devasundaram, D. Stellas, B. Chowdhury, J. Bear, R. Burns, D. Donohue, L. Pessaint, H. Andersen, M. G. Lewis, E. Terpos, M. A. Dimopoulos, A. Wlodawer, , B. K. Felber

This study compares DNA and DNA+protein vaccines in rhesus macaques, finding that co-immunization with both induces stronger antibody responses and better control of SARS-CoV-2 infection.

PLOS Pathogens · Sep 22, 2021Peer-reviewedImmunology

Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques

J. Yu, N. Collins, N. B. Mercado, K. McMahan, A. Chandrashekar, J. Liu, T. Anioke, A. Chang, V. Giffin, D. Hope, D. Sellers, F. Nampanya, S. Gardner, J. Barrett, H. Wan, , D. H. Barouch

This study evaluates the protective efficacy of oral SARS-CoV-2 delivery in rhesus macaques against respiratory challenges, finding limited immunogenicity and partial protection.

bioRxiv · Sep 13, 2021Microbiology

Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates

M. Gebre, S. Rauch, N. Roth, J. Yu, A. Chandrashekar, N. Mercado, X. He, J. Liu, K. McMahan, A. Martinot, T. Giffin, D. Hope, S. Patel, D. Sellers, O. Sanborn, , D. H. Barouch

This study compares two mRNA SARS-CoV-2 vaccines in nonhuman primates, showing that CV2CoV, with optimized non-coding regions, provides better immune responses and protection than CVnCoV.

bioRxiv · Aug 13, 2021 · PreprintImmunology

One mucosal administration of a live attenuated recombinant COVID-19 vaccine protects non-human primates from SARS-CoV-2

M. F. Tioni, R. Jordan, A. Silva Pena, A. Garg, D. Wu, S. I. Phan, X. Cheng, J. Greenhouse, T. Orekov, D. Valentin, S. Kar, L. Pessaint, H. Andersen, C. C. Stobart, M. H. Bloodworth, , R. S. Tang

This study shows that a single mucosal dose of the live attenuated RSV-based vaccine MV-014-212 protects non-human primates from SARS-CoV-2 infection by reducing viral shedding and inducing neutralizing antibodies.

bioRxiv · Jul 16, 2021Immunology

A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates

N. C. Dalvie, L. H. Tostanoski, S. A. Rodriguez-Aponte, K. Kaur, S. Bajoria, O. Kumru, A. J. Martinot, A. Chandrashekar, K. McMahan, N. B. Mercado, J. Yu, A. Chang, V. M. Giffin, F. Nampanya, S. Patel, , D. H. Barouch

This paper describes a protein subunit vaccine candidate produced in yeast that protects non-human primates against SARS-CoV-2, showing high neutralizing antibody titers and reduced viral loads after challenge.

bioRxiv · Jul 13, 2021 · PreprintImmunology

Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates

K. S. Corbett, A. Werner, S. O'Connell, M. Gagne, L. Lai, J. Moliva, B. Flynn, A. Choi, M. Koch, K. E. Foulds, S. Andrew, D. Flebbe, E. Lamb, S. T. Nurmukhambetova, S. Provost, , M. Suthar

This study evaluates mRNA-1273 vaccine efficacy against SARS-CoV-2 B.1.351 in nonhuman primates, finding that two doses significantly reduce viral replication in the airways.

bioRxiv · May 21, 2021 · PreprintImmunology

Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates

K. S. Corbett, M. C. Nason, B. Flach, M. Gagne, S. O'Connell, T. S. Johnston, S. N. Shah, V. V. Edara, K. Floyd, L. Lai, C. McDanal, J. R. Francica, B. Flynn, K. Wu, A. Choi, , Leung

This study shows that mRNA-1273 vaccine-induced antibody responses correlate with protection against SARS-CoV-2 infection in nonhuman primates.

bioRxiv · Apr 20, 2021 · PreprintImmunology

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice

C.-Y. Lai, A. To, T. A. S. Wong, M. M. Lieberman, D. E. Clements, J. T. Senda, A. H. Ball, L. Pessaint, H. Andersen, O. Donini, A. T. Lehrer

bioRxiv · Mar 2, 2021Immunology

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates

J. R. Francica, B. J. Flynn, K. E. Foulds, A. T. Noe, A. P. Werner, I. N. Morre, M. Gagne, T. S. Johnston, C. Tucker, R. L. Davis, B. Flach, S. O'Connell, S. F. Andrew, E. Lamb, D. R. Flebbe, , McDermott

This study shows that an AS03-adjuvanted SARS-CoV-2 spike protein vaccine induces strong antibody responses and protects nonhuman primates from viral challenge.

bioRxiv · Mar 2, 2021 · PreprintImmunology

Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques

X. He, A. Chandrashekar, R. C. Zahn, F. Wegmann, J. Yu, N. B. Mercado, K. McMahan, A. J. Martinot, C. Piedra-Mora, S. Beecy, S. Ducat, R. Chamanza, S. Rosendahl Huber, L. van der Fits, E. N. Borducchi, , D. H. Barouch

This study shows that low doses of Ad26.COV2.S vaccine protect rhesus macaques against SARS-CoV-2 challenge, with higher doses needed for upper respiratory tract protection.

bioRxiv · Jan 27, 2021Immunology

REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters

A. Baum, R. Copin, D. Ajithdoss, A. Zhou, K. Lanza, N. Negron, M. Ni, Y. Wei, G. S. Atwal, A. Oyejide, Y. Goez-Gazi, J. Dutton, E. Clemmons, H. M. Staples, C. Bartley, , C. A. Kyratsous

This study evaluates the efficacy of the REGN-COV2 antibody cocktail in preventing and treating SARS-CoV-2 infection in rhesus macaques and hamsters, showing reduced virus load and pathological effects.

bioRxiv · Aug 2, 2020Microbiology

Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model

A. Patel, J. Walters, E. L. Reuschel, K. Schultheis, E. Parzych, E. N. Gary, I. Maricic, M. Purwar, Z. Eblimit, S. N. Walker, D. Guimet, P. Bhojnagarwala, A. Doan, Z. Xu, D. Elwood, , K. E. Broderick

This study evaluates an intradermal DNA vaccine against SARS-CoV-2 in rhesus macaques, showing it induces immune responses and provides protection against viral challenge.

bioRxiv · Jul 28, 2020 · PreprintImmunology

CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation

B. K. Haun, C.-Y. Lai, C. A. Williams, T. A. S. Wong, M. M. Lieberman, L. Pessaint, H. A. Elyard, A. T. Lehrer

This study evaluates the adjuvant CoVaccine HT in SARS-CoV-2 Spike S1 vaccines, showing it enhances IgG titres, affinity maturation, class switching, and cell-mediated immunity compared to Alhydrogel.

bioRxiv · Jul 24, 2020Immunology